Methotrexate 2.5mg Tab
Product Overview
| Generic Name | Methotrexate 2.5mg Tab |
| Brand Name(s) | Rheumatrex, Trexall |
| Category | Antineoplastic / Cancer |
| Form | Tablets, Oral 100T |
| Strength | 2.5 mg |
| Therapeutic Class | Antimetabolite; folic acid analogue with immunosuppressant & antineoplastic activity |
| ATC Code | L04AX03 |
Manufacturing & Regulatory
| Manufacturer | Actavis, Teva |
| GMP Compliance | WHO-GMP certified |
| DMF/CEP | Type II |
| COFEPRIS | Batch-specific |
| Free Sale Certificate | Yes |
Logistics & Export
| MOQ | 10 Packs |
| Shelf Life | 36 months |
| Storage | room temperature |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 to 10 Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Yes |
| SDS-Safety Data Sheet (PDF) | Upon Request, not publicly posted |
| CTD Summary (PDF) | CTD from originator; generic use abbreviated formats |
Special Notes
(Indications & usage) Methotrexate is indicated for: • acute lymphoblastic leukemia (ALL) maintenance (20 mg/m² once weekly) • mycosis fungoides; relapsed/refractory non-Hodgkin lymphoma (metronomic) • rheumatoid arthritis (starting ~7.5 mg once weekly) • polyarticular juvenile idiopathic arthritis (starting 10 mg/m² weekly) • severe psoriasis * Also Available: Methotrexate: Presentation: 2 mg/mL Oral Solution